ALLERGAN OUTLINES OPEN SCIENCE MODEL AND HIGHLIGHTS KEY DEVELOPMENT PROGRAMS AT R&D DAY

-- Open Science Strategy Seeks to Deliver Innovation from Healthcare Ecosystem –

-- Company's Pipeline Features More Than 70 Mid-to-Late Stage Development Programs with Game-Changing Opportunities Across Seven Therapeutic Categories –

-- Clinical Data and Regulatory Milestone Updates Featured in R&D Day --

-- Allergan Builds on Open Science Strategy with Acquisition of Earfold, and Licensing of Mimetogen's Tavilermide --

DUBLIN, IRELAND – November 4, 2015 – Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today hosted its R&D day where the Company outlined its “Open Science” R&D model that is helping to build therapy area leadership and drive the Company's long-term growth. The meeting also featured highlights and upcoming milestones for game-changing late-stage pipeline development programs from across Allergan’s leading therapeutic categories.